Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III comparison of 177Lu-edotreotide versus everolimus in progressive SSTR-positive GEP-NET
2016-001897-13Phase 3Active
- Sponsor
- ITM Isotope Technologies Munich
- Start
- Mar 2017
- Modality
- Small Molecules, Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Beta-minus Emitters → Radiopharmaceuticals
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in Gastroenteropancreatic Carcinoid Tumor comparing 177Lu-edotreotide with Afinitor (2 arms). Primary endpoint: progression-free survival. Started Mar 2017; status: active.
02
Drugs
lutetium Lu 177-edotreotideeverolimus
03
Conditions
Gastroenteropancreatic Carcinoid Tumor
Beyond the preview
Go deeper on 2016-001897-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-001897-13.